RGNX - リジェネックスバイオ （REGENXBIO Inc.） リジェネックスバイオRGNXのチャート
RGNXの企業情報
| symbol | RGNx |
|---|---|
| 会社名 | REGENXBIO Inc （リジェネックスバイオ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 レジェンクスバイオ(REGENXBIO Inc.)は臨床段階のバイオテクノロジー会社である。同社の遺伝子治療製品候補は遺伝子欠損への対処、治療用タンパク質または抗体の生産を可能にするために、遺伝子を細胞に送達するように設計される。同社は代謝性疾患、神経変性疾患及び網膜疾患の治療領域にわたって製品候補を開発する。製品候補であるRGX-314は湿潤加齢性黄斑変性症（湿性AMD）の治療を目的とする。製品候補であるRGX-501はホモ接合性家族性高コレステロール血症（HoFH）の治療を目的とする。同社は2つの重度遺伝的リソソーム蓄積症、ムコ多糖症I型（MPS I）及びムコ多糖症II型（MPS II）の神経学的症状に対処するために、RGX-111とRGX-121等の製品候補を開発する。製品候補は、遺伝子送達プラットフォームであるNAV Technology Platformからウイルスベクターを利用する。 リジェネックスバイオは米国のバイオテクノロジ―企業。主に、組換型アデノウイルス(AAV)遺伝子工学療法の開発、商業化に従事する。AAV遺伝子工学療法では、ウイルス遺伝子はベクタ―を作製、欠損している箇所に治療に有効な遺伝子配列を挿入し、組換型ベクタ―を作製する。同社はAAV7やAAV8など100以上のベクタ―を開発。本社はメリ―ランド州。 regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (aav) gene therapy. regenxbio's nav® technology platform, a proprietary aav gene delivery platform, consists of exclusive rights to more than 100 novel aav vectors, including aav7, aav8, aav9 and aavrh10. regenxbio's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on regenxbio's nav technology platform. regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party nav technology platform licensees. |
| 本社所在地 | 9600 Blackwell Road Suite 210 Rockville MD 20850 USA |
| 代表者氏名 | Donald J. Hayden ドナルドJ.ヘイデン |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 240-552-8181 |
| 設立年月日 | 39630 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 139人 |
| url | www.regenxbio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/rgnx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 73.66900 |
| 終値（lastsale） | 63.6 |
| 時価総額（marketcap） | 2054829758.4 |
| 時価総額 | 時価総額（百万ドル） 241.476 |
| 売上高 | 売上高（百万ドル） 175.79800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1754.982 |
| 当期純利益 | 当期純利益（百万ドル） 78.13000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Regenxbio Inc revenues increased from $7M to $172.4M. Net income totaled $114.8M vs. loss of $36.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Investment Income increase of 36% to $2.1M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$1.30 to $3.63. |
RGNXのテクニカル分析
RGNXのニュース
REGENXBIO Announces Presentation at the Jefferies Global Healthcare Conference 2023/06/01 11:05:00 PR Newswire
ROCKVILLE, Md., June 1, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present and host one-on-one investor meetings at the Jefferies Global Healthcare Conference on Thursday, June 8, 2023. Jefferies Global Healthcare Conference Date: Thursday, June 8,…
Regenxbio''s gene therapy for Hunter syndrome gets FDA regenerative medicine status 2023/05/23 12:00:59 Seeking Alpha
The U.S. FDA granted Regenerative Medicine Advanced Therapy designation to Regenxbio''s (RGNX) gene therapy RGX-121 for Hunter syndrome. Read more here
REGENXBIO Announces NAV® Technology Platform Will Support Bespoke Gene Therapy Consortium''s First Rare Disease Clinical Portfolio 2023/05/16 21:52:00 Kwhen Finance
Regenxbio: Buy, High-Potential Stock Stagnant Due To No Near-Term Catalysts 2023/05/12 13:20:33 Seeking Alpha
Regenxbio has solid cash, a great partnership, and a pipeline with a lot of potential. Click here for more.
REGENXBIO Inc. (RGNX) Q1 2023 Earnings Call Transcript 2023/05/04 02:47:06 Seeking Alpha
REGENXBIO Inc. (NASDAQ:NASDAQ:RGNX) Q1 2023 Results Conference Call May 3, 2023 4:30 PM ETCompany ParticipantsPatrick Christmas - EVP and Chief Legal OfficerKen Mills - CEOSteve Pakola -…
REGENXBIO Inc (RGNX): Price Now Near $33.19; Daily Chart Shows Downtrend on 50 Day Basis 2021/09/01 15:19:07 ETF Daily News
The moving averages on the daily timeframe suggest a bearishness in price, as the 20, 50, 100 and 200 are all in a bearish alignment -- meaning the shorter duration moving averages are below the longer duration averages, implying a stable downward trend. The post REGENXBIO Inc (RGNX): Price Now Near $33.19; Daily Chart Shows Downtrend on 50 Day Basis appeared first on ETF Daily News .
REGENXBIO Inc (RGNX): Price Up $0.13 (0.41)% Over Past Day, Up $0.12 (0.38)% Over Past Hour 2021/08/16 15:17:03 ETF Daily News
This is a reversal of the price action on the previous hour, in which price moved down. The post REGENXBIO Inc (RGNX): Price Up $0.13 (0.41)% Over Past Day, Up $0.12 (0.38)% Over Past Hour appeared first on ETF Daily News .
REGENXBIO Inc. (RGNX) CEO Ken Mills on Q2 2021 Results - Earnings Call Transcript 2021/08/10 03:31:05 Seeking Alpha
REGENXBIO Reports Second Quarter 2021 Financial Results and Operational Highlights 2021/08/09 20:05:00 PR Newswire
ROCKVILLE, Md., Aug. 9, 2021 /PRNewswire/ -- Enrollment in RGX-314 programs is on-track, including the pivotal program for the treatment of wet AMD utilizing subretinal delivery, and the Phase II trials for the treatment of wet AMD and DR utilizing in-office suprachoroidal delivery
REGENXBIO Reports Second Quarter 2021 Financial Results and Operational Highlights 2021/08/09 20:05:00 PR Newswire
ROCKVILLE, Md., Aug. 9, 2021 /PRNewswire/ -- Enrollment in RGX-314 programs is on-track, including the pivotal program for the treatment of wet AMD utilizing subretinal delivery, and the Phase II trials for the treatment of wet AMD and DR utilizing in-office suprachoroidal delivery
Gene Therapy For Cancer Market: Comprehensive Study Explore Huge Growth in Future | GLIEAD, REGENXBIO, Autolus 2021/07/29 15:07:00 iCrowdNewswire
The Gene Therapy For Cancer market research report added by Report Ocean, is an in-depth analysis of the latest developments, market size, status, upcoming technologies, industry drivers, challenges, regulatory policies, with []